{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:05:30Z","timestamp":1746504330288,"version":"3.40.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100022905","name":"SUNY Upstate Medical University Upstate Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clgc.2024.102193","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T02:03:42Z","timestamp":1724378622000},"page":"102193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of Cytoreductive Nephrectomy in Metastatic Clear Cell Renal cell Carcinoma in the Era of immunotherapy: An Analysis of the National Cancer Database"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9229-3079","authenticated-orcid":false,"given":"Maroun Bou","family":"Zerdan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Niforatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swathi","family":"Arunachalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Jamaspishvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2243-1990","authenticated-orcid":false,"given":"Roger","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennady","family":"Bratslavsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-2596","authenticated-orcid":false,"given":"Jeffrey","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6033-6943","authenticated-orcid":false,"given":"Alina","family":"Basnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clgc.2024.102193_bib0001","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.euo.2019.04.007","article-title":"Individualised indications for cytoreductive nephrectomy: which criteria define the optimal candidates?","volume":"2","author":"Larcher","year":"2019","journal-title":"European Urology Oncology"},{"issue":"3","key":"10.1016\/j.clgc.2024.102193_bib0002","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/01.ju.0000110610.61545.ae","article-title":"Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis","volume":"171","author":"Flanigan","year":"2004","journal-title":"J Urol"},{"issue":"9286","key":"10.1016\/j.clgc.2024.102193_bib0003","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet North Am Ed"},{"issue":"4","key":"10.1016\/j.clgc.2024.102193_bib0004","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.eururo.2020.04.038","article-title":"Deferred cytoreductive nephrectomy in patients with newly diagnosed metastatic renal cell carcinoma","volume":"78","author":"Bhindi","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102193_bib0005","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102193_bib0006","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2021.06.009","article-title":"Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy?","volume":"80","author":"M\u00e9jean","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102193_bib0007","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.eururo.2022.10.004","article-title":"Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"83","author":"Bakouny","year":"2023","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102193_bib0008","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2014.05.034","article-title":"Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"66","author":"Heng","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102193_bib0009","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.juro.2010.09.012","article-title":"The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy","volume":"185","author":"Choueiri","year":"2011","journal-title":"J Urol"},{"issue":"10189","key":"10.1016\/j.clgc.2024.102193_bib0010","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet North Am Ed"},{"issue":"9","key":"10.1016\/j.clgc.2024.102193_bib0011","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clgc.2024.102193_bib0012","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102193_bib0013","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","article-title":"The National Cancer Data Base: a powerful initiative to improve cancer care in the United States","volume":"15","author":"Bilimoria","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102193_bib0014","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncol"},{"issue":"47","key":"10.1016\/j.clgc.2024.102193_bib0015","first-page":"4457","article-title":"Radical nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma","volume":"11","author":"Yanagisawa","year":"2023","journal-title":"European Urology Focus"},{"issue":"47","key":"10.1016\/j.clgc.2024.102193_bib0016","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.18632\/oncotarget.27807","article-title":"A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial","volume":"11","author":"de Velasco","year":"2020","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.clgc.2024.102193_bib0017","doi-asserted-by":"crossref","first-page":"150.e1","DOI":"10.1016\/j.urolonc.2022.11.022","article-title":"Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy","volume":"41","author":"Riveros","year":"2023","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"key":"10.1016\/j.clgc.2024.102193_bib0018","doi-asserted-by":"crossref","first-page":"S1224","DOI":"10.1016\/j.annonc.2022.07.1584","article-title":"1481TiP A prospective, randomized phase II trial of neoadjuvant immunotherapy in primary clear cell renal cancer at risk for recurrence or distant metastases: The NESCIO trial","volume":"33","author":"Burgers","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102193_bib0019","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/iju.14841","article-title":"Surgical and focal treatment for metastatic renal cell carcinoma: a literature review","volume":"29","author":"Naito","year":"2022","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2024.102193_bib0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/EDBK_320785","article-title":"Next steps: sequencing therapies in metastatic kidney cancer in the contemporary era","volume":"41","author":"Schmidt","year":"2021","journal-title":"American Society of Clinical Oncology Educational Book"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T16:43:04Z","timestamp":1746463384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1558767324001630"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102193","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Cytoreductive Nephrectomy in Metastatic Clear Cell Renal cell Carcinoma in the Era of immunotherapy: An Analysis of the National Cancer Database","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102193"}}